A holistic approach to low vision rehabilitation needed

Article

A more holistic approach to patient referral and rehabilitation provision for people with low vision is required.

A more holistic approach to patient referral and rehabilitation provision for people with low vision is required, according to a report published in the February issue of the British Journal of Ophthalmology.

P. M O'Connor and colleagues from the Centre for Eye Research Australia, University of Melbourne and Vision CRC, Sydney, Australia conducted a study to determine the independent predictors of rehabilitation needs for people with low vision using the Impact of Vision Impairment questionnaire (IVI).

A total of 477 patients attending low vision clinics completed the IVI and provided personal and clinical information such as co-morbidities and visual acuity (VA). Rasch analysis was used to generate person measures for the IVI total and three domain scores. Rehabilitation needs were based on mild, moderate or severe levels of restriction in participation as determined by the lower, moderate and higher tertiles of persons' measures. Logistic regression analyses were used to determine independent predictors of rehabilitation needs.

The majority of patients (74%) had moderate or severe vision loss and 43% had age-related macular degeneration (AMD). The results demonstrated that women, shorter duration of vision impairment, the presence of AMD, worse VA, a greater impact of co-morbidities on daily living and reliance on family or friends were univariately associated with poorer IVI scores (p<0.05). In all regression models, VA, the impact of co-morbidities on daily living and dependence on family or friends emerged as the three strongest independent predictors of rehabilitation needs.

The study concluded that, in addition to vision, clinicians should also consider issues relating to dependency when assessing rehabilitation needs.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.